KYMR
Kymera Therapeutics Inc
$43.51
Earnings Summary
Revenue | $3.74Mn |
Net Profits | $-62.49Mn |
Net Profit Margins | -1670.33% |
Highlights
Kymera Therapeutics Inc’s revenue fell -20.88% since last year same period to $3.74Mn in the Q3 2024. On a quarterly growth basis, Kymera Therapeutics Inc has generated -85.42% fall in its revenue since last 3-months.
Kymera Therapeutics Inc’s net profit fell -18.2% since last year same period to $-62.49Mn in the Q3 2024. On a quarterly growth basis, Kymera Therapeutics Inc has generated -48.56% fall in its net profits since last 3-months.
Kymera Therapeutics Inc’s net profit margin fell -49.38% since last year same period to -1670.33% in the Q3 2024. On a quarterly growth basis, Kymera Therapeutics Inc has generated -918.59% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Kymera Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Year | -0.73 |
Highlights
Kymera Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.73.
Key Ratios
Key ratios of the Kymera Therapeutics Inc post its Q3 2024 earnings
Earning Per Share (EPS) | -0.82 |
Highlights
Kymera Therapeutics Inc’s earning per share (EPS) jumped 8.89% since last year same period to -0.82 in the Q3 2024. This indicates that the Kymera Therapeutics Inc has generated 8.89% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-08-07 | -0.68 | -0.58 | 14.71% |
2024-05-02 | -0.73 | -0.62 | 15.07% |
2024-10-31 | -0.84 | -0.82 | 2.38% |
₹0 US Stocks a/c Opening Fee